ClinicalTrials.gg
CompletedNCT00242814Updated Dec 8, 2023

Phase IV, 9 Weeks Comparison Between MICARDIS 80 mg and Amlodipine 10 mg on Biological PPAR Gamma Activities

A Phase 4 interventional study of Micardis and Amlodipine in Hypertension and Metabolic Syndrome X, sponsored by Boehringer Ingelheim. Completed at 31 sites in France. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-08.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 99 studies testing telmisartan in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Telmisartan · Hypertension.

Enrollment
61st of 99
100 · median 184
Started
2005
with 5 others
Phase 4
32 of 99
1 open now
Registered
13th of 99
by date
Lead sponsor
48 of 99
Boehringer Ingelheim

Among the 99 studies testing telmisartan in Hypertension, this one is the 61st largest by enrollment, is one of 6 that started in 2005, is one of 32 in phase 4, and was the 13th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 99 studies testing telmisartan in Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About telmisartan

Telmisartan: first FDA approval 1998 (MICARDIS), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies testing telmisartan in Hypertension, or all of them as a file.
02

Study summary

The objective of the study is to compare PPAR activities (increase of adiponectin level) between MICARDIS and amlodipine after 6 weeks of treatment in hypertensive patients with metabolic syndrome. Moreover, this study will compare serum level of inflammatory markers of the metabolic syndrome after 6 weeks of treatment.

An ancillary study performed in one center will assess adipocyte differentiation (PPAR gamma stimulation) in 30 subjects (15 per arm).

03

Conditions studied

  • Hypertension
  • Metabolic Syndrome X
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patient written is signed prior to any trial specific procedures participation

  • male patients > 18 years
  • Mean seated SBP > 130mmHg and/or DBP > 85mmHg treated with antihypertensive drug(s)
  • with at least 2 more criteria of metabolic syndrome (NCEPT III). Biological data available within 6 months prior to enrollment visit.
  • abdominal obesity > 102 cm at screening
  • TG > 1.5 g/l
  • HDL \< 0.4 g/l
  • Glycemia > 6 mmol/l

Exclusion criteria

Exclusion Criteria:

Patients with any of the following conditions will be excluded from trial:

  • confirmed type 1 or 2 diabetic patients treated or not
  • secondary hypertension
  • Mean seated SBP>180 mmHg and/or DBP >110 mmHg at screening
  • hepatic and/or renal dysfunction as defined by the following laboratory parameters at visit 1:
  • (ALT) or SGOT (AST) ¿ twice the
  • serum creatinine ¿ 2.3 mg/dL (or 203 ¿mol/L)
  • bilateral renal artery stenosis or renal artery stenosis in a solitary kidney
  • patients post-renal transplant or with only one functioning kidney
  • hypokalemia or hyperkalemia at visit 1
  • uncorrected volume or sodium depletion at visit 1
  • primary aldosteronism
  • hereditary or known fructose intolerance
  • biliary obstructive disorders
  • patients who have previously experienced symptoms characteristic of angioedema during treatment with angiotensin-II receptor antagonists
  • history of drug or alcohol dependency within the previous six months
  • concurrent participation in another clinical trial or any therapy within thirty days prior to signing the consent form
  • symptomatic congestive heart failure (New York Heart Academy () functional class CHF II-IV)
  • unstable angina pectoris, myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) surgery less than three months prior to
  • stroke less than six months prior to informed consent
  • sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant arrhythmias as determined by the investigator
  • hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the aortic or mitral valve
  • known allergic to any component of the formulations under investigation
  • concomitant therapy with lithium, cholestyramine or colestipol resins continued after visit 1
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Enrollment
100 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Comparison of the serum adiponectin level at the end of study (6 weeks) between the two groups.

    Time frame: At week 6

Secondary outcomes

  1. Comparison of serum level of TNF alpha, IL-6, leptine, hsCRP, TG, HDL and blood pressure control between two groups. Adipocyte differentiation in 30 patients (PPAR gamma stimulation) between two groups.

    Time frame: At week 6

07

Study locations

31 sites
  • 502.486.3302A Cabinet Médical
    Angers, France
  • 502.486.3302B Cabinet Médical
    Angers, France
  • 502.486.3303A Boehringer Ingelheim Investigational Site
    Angers, France
  • 502.486.3305A Cabinet Médical
    Angers, France
  • 502.486.3323A Cabinet Médical
    Angers, France
  • 502.486.3323B Cabinet Médical
    Angers, France
  • 502.486.3324A Cabinet Médical
    Angers, France
  • 502.486.3324B Cabinet Médical
    Angers, France
  • 502.486.3325A Cabinet médical
    Angers, France
  • 502.486.3326A Cabinet Médical
    Angers, France
  • 502.486.3328A Cabinet Médical
    Angers, France
  • 502.486.3306A Cabinet Médical
    Briollay, France
  • 502.486.3307A Cabinet Médical
    Chemille, France
  • 502.486.3319A Cabinet Médical
    Cherbourg, France
  • 502.486.3320A Cabinet Médical
    Cherbourg, France
  • 502.486.3320B Cabinet Médical
    Cherbourg, France
  • 502.486.3321A Cabinet Médical
    Equeurdreville, France
  • 502.486.3322A Boehringer Ingelheim Investigational Site
    Evron, France
  • 502.486.3312A Cabinet Médical
    Feneu, France
  • 502.486.3315A Cabinet Médical
    La Rochelle, France
  • 502.486.3308A Cabinet Médical
    Montrevault, France
  • 502.486.3316A Boehringer Ingelheim Investigational Site
    Nieul sur Mer, France
  • 502.486 3301A Boehringer Ingelheim Investigational Site
    Paris, France
  • 502.486.3301B Hôpital Pitié Salpêtrière
    Paris, France
  • 502.486.3310A Cabinet Médical
    Saint Pierre Montlimard, France
  • 502.486.3327A Cabinet Médical
    Saumur, France
  • 502.486.3309A Cabinet Médical Jean Charcot
    Segre, France
  • 502.486.3311A Cabinet Médical
    Tierce, France
  • 502.486.3311B Cabinet Médical
    Tierce, France
  • 502.486.3311C Cabinet Médical
    Tierce, France
  • 502.486.3311D Cabinet Médical
    Tierce, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2005 to primary completion in Mar 2007, 16 months.

Of 35 industry-sponsored phase 4 interventional studies under Hypertension, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 16 months is below that.

Counting every sponsor, half of 161 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2005
First posted
Oct 21, 2005
StartActual
Nov 3, 2005
Primary completionActual
Mar 29, 2007
Last update
Dec 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00242814
Responsible party
Sponsor
First posted
Oct 21, 2005
Start date
Nov 3, 2005
Primary completion
Mar 29, 2007
Last update
Dec 8, 2023

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Telmisartan · Amlodipine

Start the discussion